原发性乳腺癌未行手术切除冷冻消融后的MRI表现
回顾性评估54例≤15mm、核分级1-2级、雌激素受体阳性/人表皮生长因子2阴性且无淋巴结转移的导管原位癌或浸润性癌患者,冷冻消融后未行手术切除的系列MRI表现。首次消融后MRI有7例(13.0%)发现可疑区域,与病灶呈焦点至肿块型及两名观察者均怀疑残留或复发显著相关(p<0.001);第二次消融后MRI无两名观察者同时发现可疑病灶,可疑表现可在后续辅助治疗和随访中消退。
要点
- 冷冻消融后首次MRI(22-171天)有7例(13.0%)发现可疑区域,第二次MRI(82-487天)无两名观察者同时发现可疑病灶。
- 首次MRI可疑区域与病灶呈焦点至肿块型及两名观察者均怀疑残留或复发显著相关(p<0.001)。
- 观察者间对MRI表现的一致性为一般至中等(κ=0.356-0.434)。
核心结论
- 首次冷冻消融后MRI可在治疗区域内检测到可疑表现,这些表现可在后续辅助治疗和随访中消退。
研究设计与样本
- 回顾性研究,经机构审查委员会批准并豁免知情同意,纳入54例导管原位癌或浸润性癌(≤15mm、核分级1或2级、雌激素受体阳性/人表皮生长因子2阴性、无淋巴结转移)行冷冻消融且未后续切除的患者,两名观察者独立审阅消融后前两次MRI。
关键影像表现/征象
- 首次冷冻消融后MRI(22-171天)有7例(13.0%)被观察者1或2识别出可疑区域。
- 可疑区域与病灶呈焦点至肿块型(对比非焦点至肿块型:非肿块强化或无强化)显著相关(p<0.001)。
- 可疑区域与两名观察者均怀疑残留或复发显著相关(p<0.001)。
- 第二次冷冻消融后MRI(82-487天)无两名观察者同时发现可疑表现的病例。
诊断标准与关键数值
- 观察者间对MRI表现的一致性为一般至中等(κ=0.356-0.434)。
- 首次消融后MRI可疑区域7例(13.0%),与焦点至肿块型及两名观察者均怀疑残留或复发显著相关(p<0.001)。
临床应用与阅片要点
- 首次冷冻消融后MRI可在治疗区域内出现可疑表现,这些表现可在后续辅助治疗和随访中消退。
- 观察者间一致性为一般至中等(κ=0.356-0.434),阅片时需注意判读差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To retrospectively evaluate findings on serial magnetic resonance imaging (MRI) after cryoablation for breast cancer lesions without subsequent surgical resection.
MATERIALS AND METHODS: This study was approved by the Institutional Review Board and the requirement to obtain informed consent waived. Ductal carcinoma in situ or invasive carcinoma ≤15 mm, nuclear grade 1 or 2, estrogen receptor positive/human epidermal growth factor 2 negative without lymph node metastasis were treated with cryoablation without subsequent excision. Two observers independently reviewed the first two postcryoablation MRIs for shape (none, focus-to-mass, or nonmass enhancement) and suspicion of residual disease (positive or negative). Fisher's exact or the Mann-Whitney U test was used to assess significance. Interobserver agreement on findings was evaluated by calculating κ values.
RESULTS: Fifty-four patients were enrolled. The first and second postcryoablation MRIs were performed 22-171 days and 82-487 days after cryoablation, respectively. Interobserver agreement ranged from fair to moderate (κ = 0.356-0.434). Observer 1 or 2 identified suspicious areas on the first postcryoablation MRI in seven cases (13.0%). These were significantly associated with focus-to-mass shape (vs non-focus-to-mass: nonmass enhancement or none) and residual disease or recurrence suspected by both observers (p < 0.001). There were no cases of both observers identifying suspicious findings on the second postcryoablation MRI.
CONCLUSION: Suspicious findings can be detected within the treated area at the first postcryoablation MRI. These can resolve during subsequent adjuvant therapies and follow-up.
引用
- Machida Y, Shimauchi A, Igarashi T, et al. MRI Findings After Cryoablation of Primary Breast Cancer Without Surgical Resection. Acad Radiol. 2018. PMID: 30149977. doi:10.1016/j.acra.2018.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。